Literature DB >> 19630834

Vascular K ATP channels: dephosphorylation and deactivation.

Paolo Tammaro1.   

Abstract

Vascular ATP-sensitive potassium (K(ATP)) channels (Kir6.1/SUR2B) are regulated by both cell metabolism and chemical transmitters. They are the target for a number of vasodilators and vasoconstrictors whose mechanisms of action involve activation of protein kinase A (PKA) and protein kinase C (PKC), respectively. The article by Orie et al. in this issue of the BJP sheds new light on the (opposing) role of protein phosphatases in the regulation of this ion channel activity. Their data suggest that calcineurin, a Ca(2+)-dependent protein phosphatase, modulates Kir6.1/SUR2B by inhibiting PKA-dependent phosphorylation of the channel. This novel mechanism may provide a modulation opposing the action of vasodilators on the K(ATP) channel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19630834      PMCID: PMC2707967          DOI: 10.1111/j.1476-5381.2009.00204.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  12 in total

1.  Calcium modulation of vascular smooth muscle ATP-sensitive K(+) channels: role of protein phosphatase-2B.

Authors:  A J Wilson; R I Jabr; L H Clapp
Journal:  Circ Res       Date:  2000-11-24       Impact factor: 17.367

2.  Multisite phosphorylation mechanism for protein kinase A activation of the smooth muscle ATP-sensitive K+ channel.

Authors:  Kathryn V Quinn; Jonathan P Giblin; Andrew Tinker
Journal:  Circ Res       Date:  2004-04-15       Impact factor: 17.367

3.  cAMP-dependent protein kinase phosphorylation produces interdomain movement in SUR2B leading to activation of the vascular KATP channel.

Authors:  Yun Shi; Xianfeng Chen; Zhongying Wu; Weiwei Shi; Yang Yang; Ningren Cui; Chun Jiang; Robert W Harrison
Journal:  J Biol Chem       Date:  2008-01-15       Impact factor: 5.157

Review 4.  ATP-sensitive and inwardly rectifying potassium channels in smooth muscle.

Authors:  J M Quayle; M T Nelson; N B Standen
Journal:  Physiol Rev       Date:  1997-10       Impact factor: 37.312

5.  Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1.

Authors:  Takashi Miki; Masashi Suzuki; Tadao Shibasaki; Hiroko Uemura; Toshiaki Sato; Kaori Yamaguchi; Haruhiko Koseki; Toshihiko Iwanaga; Haruaki Nakaya; Susuma Seino
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

6.  Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 K(ATP) channels.

Authors:  William A Chutkow; Jielin Pu; Matthew T Wheeler; Tomoyuki Wada; Jonathan C Makielski; Charles F Burant; Elizabeth M McNally
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

7.  PKA phosphorylation of SUR2B subunit underscores vascular KATP channel activation by beta-adrenergic receptors.

Authors:  Yun Shi; Zhongying Wu; Ningren Cui; Weiwei Shi; Yang Yang; Xiaoli Zhang; Asheebo Rojas; Binh T Ha; Chun Jiang
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2007-06-27       Impact factor: 3.619

8.  Ca2+/calcineurin regulation of cloned vascular K ATP channels: crosstalk with the protein kinase A pathway.

Authors:  N N Orie; A M Thomas; B A Perrino; A Tinker; L H Clapp
Journal:  Br J Pharmacol       Date:  2009-05-07       Impact factor: 8.739

9.  Transgenic expression of a dominant negative K(ATP) channel subunit in the mouse endothelium: effects on coronary flow and endothelin-1 secretion.

Authors:  Brian Malester; Xiaoyong Tong; Ioana Ghiu; Andrianos Kontogeorgis; David E Gutstein; Jie Xu; Karen D Hendricks-Munoz; William A Coetzee
Journal:  FASEB J       Date:  2007-03-06       Impact factor: 5.191

10.  Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide.

Authors:  Mervyn Singer; Flaminia Coluzzi; Alastair O'Brien; Lucie H Clapp
Journal:  Lancet       Date:  2005 May 28-Jun 3       Impact factor: 79.321

View more
  1 in total

1.  Endothelium in pharmacology: 30 years on.

Authors:  J C McGrath
Journal:  Br J Pharmacol       Date:  2009-06       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.